The result is a gradual depletion of B12 stores that can take months to become clinically apparent but may cause fatigue , dizziness , and neurological symptoms long before a blood test catches the deficiency
While, previously, patients with severe OSA would likely require CPAP therapy for the remainder of their lives, especially as OSA tends to worsen with age and weight increase, these obesity-targeting medications offer the potential for some patients to become less dependent on CPAP or be managed using lower, more tolerable pressures. Indeed, patients on tirzepatide had about a 50% reduction in the apnea-hypopnea index and significant improvements in hypoxemia
Regulatory bodies such as the European Medicines Agency (EMA) classify NAION as a very rare side effect , affecting up to 1 in 10,000 people taking semaglutide
Tirzepatide alone achieves 20-22% weight loss in SURMOUNT trials, while orlistat alone achieves 3-5%
Your insurance company may require prior authorization or step therapy (a trial of less expensive weight loss medications) before approving GLP-1 drugs